Viking Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Viking Therapeutics, Inc. (VKTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-07-29
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 0.00 shares.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 0.00 shares.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 0.00 shares.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 52.50K shares, a 92.66% increase from fiscal 2024.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 27.25K shares.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 30.00K shares, a 77.40% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | 0.00 shares 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-04-30 | ||||
| 2025-12-31 | 52.50K shares 10-K · filed 2026-02-11 | ||||
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-23 | 0.00 shares 10-Q · filed 2025-07-23 | 15.00K shares derived: sum of 3 quarters · filed 2026-02-11 | 27.25K shares derived: sum of 4 quarters · filed 2026-02-11 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-04-24 | 15.00K shares derived: sum of 2 quarters · filed 2026-02-11 | 27.25K shares derived: sum of 3 quarters · filed 2026-02-11 | 27.25K shares derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-12-31 | 15.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 27.25K shares derived: sum of 2 quarters · filed 2026-02-11 | 27.25K shares derived: sum of 3 quarters · filed 2026-02-11 | 27.25K shares 10-K · filed 2026-02-11 | |
| 2024-09-30 | 12.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-23 | 12.25K shares derived: sum of 2 quarters · filed 2024-10-23 | 12.25K shares 10-Q · filed 2024-10-23 | 12.25K shares derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | 0.00 shares 10-Q · filed 2024-07-24 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-11 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-04-25 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-11 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-11 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-11 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-11 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-11 | 0.00 shares 10-K · filed 2026-02-11 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | 0.00 shares derived: sum of 2 quarters · filed 2023-10-25 | 0.00 shares 10-Q · filed 2023-10-25 | 0.00 shares derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | 0.00 shares 10-Q · filed 2023-07-26 | 0.00 shares derived: sum of 3 quarters · filed 2025-02-26 | 0.00 shares derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-04-26 | 0.00 shares derived: sum of 2 quarters · filed 2025-02-26 | 0.00 shares derived: sum of 3 quarters · filed 2025-02-26 | 15.00K shares derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 0.00 shares derived: sum of 2 quarters · filed 2025-02-26 | 15.00K shares derived: sum of 3 quarters · filed 2025-02-26 | 30.00K shares 10-K · filed 2025-02-26 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | 15.00K shares derived: sum of 2 quarters · filed 2022-10-26 | 30.00K shares 10-Q · filed 2022-10-26 | -94.31K shares derived: sum of 4 quarters · filed 2024-02-07 | |
| 2022-06-30 | 15.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | 30.00K shares 10-Q · filed 2022-07-27 | -94.31K shares derived: sum of 3 quarters · filed 2024-02-07 | -13.64K shares derived: sum of 4 quarters · filed 2024-02-07 | |
| 2022-03-31 | 15.00K shares 10-Q · filed 2022-04-27 | -109.31K shares derived: sum of 2 quarters · filed 2024-02-07 | -28.64K shares derived: sum of 3 quarters · filed 2024-02-07 | ||
| 2021-12-31 | -124.31K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | -43.64K shares derived: sum of 2 quarters · filed 2024-02-07 | 132.75K shares 10-K · filed 2024-02-07 | ||
| 2021-09-30 | 80.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 257.06K shares 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | 176.38K shares 10-Q · filed 2021-07-28 | ||||
| 2020-12-31 | -6.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | 55.25K shares derived: sum of 2 quarters · filed 2022-02-09 | 77.25K shares 10-K · filed 2022-02-09 | 83.50K shares 10-K · filed 2021-02-17 | |
| 2020-09-30 | 61.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | 83.50K shares 10-Q · filed 2020-10-28 | |||
| 2020-06-30 | 22.00K shares 10-Q · filed 2020-07-29 | ||||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | 193.03K shares derived: sum of 2 quarters · filed 2021-02-17 | 207.02K shares 10-K · filed 2021-02-17 | ||
| 2019-09-30 | 193.03K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | 207.02K shares 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | 13.99K shares 10-Q · filed 2019-08-01 | ||||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | 0.00 shares derived: sum of 2 quarters · filed 2020-02-26 | 0.00 shares derived: sum of 3 quarters · filed 2020-02-26 | 18.75K shares 10-K · filed 2020-02-26 | |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | 0.00 shares derived: sum of 2 quarters · filed 2018-11-07 | 18.75K shares 10-Q · filed 2018-11-07 | 18.75K shares derived: sum of 4 quarters · filed 2019-03-13 | |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 18.75K shares 10-Q · filed 2018-08-09 | 18.75K shares derived: sum of 3 quarters · filed 2019-03-13 | 98.75K shares derived: sum of 4 quarters · filed 2019-03-13 | |
| 2018-03-31 | 18.75K shares 10-Q · filed 2018-05-09 | 18.75K shares derived: sum of 2 quarters · filed 2019-03-13 | 98.75K shares derived: sum of 3 quarters · filed 2019-03-13 | 98.75K shares derived: sum of 4 quarters · filed 2019-03-13 | |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | 80.00K shares derived: sum of 2 quarters · filed 2019-03-13 | 80.00K shares derived: sum of 3 quarters · filed 2019-03-13 | 178.48K shares 10-K · filed 2019-03-13 | |
| 2017-09-30 | 80.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | 80.00K shares derived: sum of 2 quarters · filed 2017-11-08 | 178.48K shares 10-Q · filed 2017-11-08 | 230.60K shares derived: sum of 4 quarters · filed 2018-03-07 | |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | 98.48K shares 10-Q · filed 2017-08-09 | 150.60K shares derived: sum of 3 quarters · filed 2018-03-07 | ||
| 2017-03-31 | 98.48K shares 10-Q · filed 2017-05-10 | 150.60K shares derived: sum of 2 quarters · filed 2018-03-07 | |||
| 2016-12-31 | 52.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | 102.38K shares 10-K · filed 2018-03-07 | |||
| 2016-09-30 | 50.25K shares 10-Q · filed 2016-11-10 | ||||
| 2015-12-31 | 44.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | 78.50K shares derived: sum of 2 quarters · filed 2016-03-08 | 78.50K shares 10-K · filed 2016-03-08 | ||
| 2015-09-30 | 33.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | 33.75K shares 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | 0.00 shares 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |